Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression
In conclusion, germacrone reversed adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-gp expression. The results indicated that germacrone might be a new MDR reversal agent for CML chemotherapy.
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
More News: Biochemistry | Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Genetics | Leukemia | Multidrug Resistance | Study